In a recent study published by STEM CELLS, a research group from Stanford University describes a novel regimen for quashing the immunologic barrier with a short-course treatment of two costimlation-adhesion blockade agents, to allow engraftment of transplanted differentiated stem cells and their prolonged survival in tissue.
http://www.prweb.com/releases/2013/8/prweb11033138.htm
http://www.prweb.com/releases/2013/8/prweb11033138.htm
No comments:
Post a Comment